Metaraminol in septic shock patients, a multicenter feasibility trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045337

Enrollment

Unknown

Registered

2021-04-13

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic shock

Interventions

experimental group:Metaraminol

control group:Norepinephrine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as septic shock.

Exclusion criteria

Exclusion criteria: 1.The application of metaraminol exceeds the maximum dose specified in the drug instructions; 2.Patients or family members did not agree to be enrolled.

Design outcomes

Primary

Measure	Time frame
Mean blood pressure;	—

Secondary

Measure	Time frame
Cytokines;T cell subsets;	—

Countries

China

Contacts

Public ContactXing Xuezhong

Cancer Hospital of Chinese Academy of Medical Sciences

xingxuezhong@cicams.ac.cn+86 10 18601141437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026